Citizens JMP Reiterates Market Outperform Rating on Esperion Therapeutics (ESPR)

Citizens JMP analyst Jason N. Butler reiterated a Market Outperform rating and $4.00 price target on Esperion Therapeutics (NASDAQ: ESPR).

The analyst commented, "Approval in one of the top three markets underscore growth opportunity; we reiterate our Market Outperform rating and risk-adjusted, DCF-derived $4 price target on Esperion Therapeutics. This morning, Esperion announced that partner Otsuka received regulatory approval in Japan for NEXLETOL to treat hypercholesterolemia and familial hypercholesterolemia in Japan. Japan is among one of the three largest cardiovascular prevention markets globally. In our view, Otsuka’s established cardiorenal commercial leadership in Japan positions it well to execute well on the NEXLETOL launch."

For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.

Shares of Esperion Therapeutics closed at $2.66 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Bernstein SocGen Group Starts Cipher Mining (CIFR) at Outperform
• Redwire Defense wins $15.9M Army contract for drone systems